SCHEMBL496799

SCHEMBL496799

Cc1cc2c(s1)-c1c(c(C(=O)NN3CCCCC3)nn1-c1ccc(Cl)cc1Cl)C2

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 9/20 0.71
▸ CNR1 P21554 8/20 0.71
▸ TDP1 Q9NUW8 1/20 0.71
▸ ABCC4 O15439 1/20 0.63
▸ MLNR O43193 1/20 0.63
▸ ABCB11 O95342 1/20 0.63
▸ CHRM2 P08172 1/20 0.63
▸ ADORA3 P0DMS8 1/20 0.63
▸ CYP2C9 P11712 1/20 0.63
▸ ADRA2B P18089 1/20 0.63
▸ ADRA2C P18825 1/20 0.63
▸ DRD1 P21728 1/20 0.63
▸ TBXA2R P21731 1/20 0.63
▸ SLC6A2 P23975 1/20 0.63
▸ HRH2 P25021 1/20 0.63
▸ HTR2A P28223 1/20 0.63
▸ AGTR1 P30556 1/20 0.63
▸ CCKAR P32238 1/20 0.63
▸ CCKBR P32239 1/20 0.63
▸ MC4R P32245 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL497103 0.86 CNR2 (0.71) CNR2CNR1TDP1
SCHEMBL496034 0.84 CNR2 (0.49) CNR2CNR1TDP1
SCHEMBL496281 0.84 CNR2 (0.74) CNR2CNR1
SCHEMBL496289 0.84 CNR2 (0.74) CNR2CNR1
SCHEMBL14746942 0.83 CNR2 (0.88) CNR2CNR1TDP1
SCHEMBL14746932 0.83 CNR2 (0.81) CNR2CNR1TDP1
SCHEMBL3021073 0.83 CNR2 (1.00) CNR2CNR1TDP1
SCHEMBL14746913 0.83 CNR2 (0.81) CNR2CNR1TDP1
SCHEMBL30544878 0.83 CNR2 (1.00) CNR2CNR1TDP1
SCHEMBL14742094 0.83 CNR2 (0.81) CNR2CNR1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012022865-A3 DEVICE FOR ASSEMBLING A VEHICLE ENGINE AUTOMATIC STOP-START ASSEMBLY ON THE BODY SHELL STRUCTURE OF THE VEHICLE AND ASSOCIATED METHOD OF ASSEMBLY Peugeot Citroën Automobiles SA (FR) 2012-05-10 — — WO claimed
EP-1602658-B1 Tricyclic pyrazole derivatives as cannabinoid receptor antagonists NEUROSCIENZE PHARMANESS S C A R L (IT) 2011-12-07 — — EP claimed
US-7485730-B2 Pharmaceutical compounds NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) 2009-02-03 — — US claimed
US-20050282798-A1 Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) 2005-12-22 — — US claimed
EP-1602658-A1 Tricyclic pyrazole derivatives as cannabinoid receptor antagonists Neuroscienze Oharmaness S.c.a.r.l. (IT) 2005-12-07 — — EP claimed
WO-2012022865-A3 DEVICE FOR ASSEMBLING A VEHICLE ENGINE AUTOMATIC STOP-START ASSEMBLY ON THE BODY SHELL STRUCTURE OF THE VEHICLE AND ASSOCIATED METHOD OF ASSEMBLY Peugeot Citroën Automobiles SA (FR) 2012-05-10 — — WO disclosed
US-20120088751-A1 PHARMACEUTICAL COMPOUNDS NEUROSCIENCZE PHARMANESS S.C. A R.L. (IT) 2012-04-12 — — US disclosed
US-8106218-B2 Pharmaceutical compounds NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) 2012-01-31 — — US disclosed
EP-1602658-B1 Tricyclic pyrazole derivatives as cannabinoid receptor antagonists NEUROSCIENZE PHARMANESS S C A R L (IT) 2011-12-07 — — EP disclosed
US-20090081123-A1 PHARMACEUTICAL COMPOUNDS CENERX BIOPHARMA (US) 2009-03-26 — — US disclosed
US-7485730-B2 Pharmaceutical compounds NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) 2009-02-03 — — US disclosed
US-20050282798-A1 Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation NEUROSCIENZE PHARMANESS S.C. A R.L. (IT) 2005-12-22 — — US disclosed
EP-1602658-A1 Tricyclic pyrazole derivatives as cannabinoid receptor antagonists Neuroscienze Oharmaness S.c.a.r.l. (IT) 2005-12-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282798-A1 Tricyclic pyrazole derivatives having affinity for cannabinoidergic CB1 and/or CB2 receptors; less side effects on the central nervous system; N-piperidinyl-7-chloro-1-(2',4'-dichlorophenyl)-4,5-dihydro-1H-thieno[2,3-g]indazol-3-carboxamide; immune disorders, osteoporosis, renal ischemia, inflammation CNR2, CNR1, GPR55 CNR2 1/4885CNR1 2/4885TDP1 4833/4885
US-20120088751-A1 PHARMACEUTICAL COMPOUNDS CNR2, CNR1, OPRK1 CNR2 1/4885CNR1 2/4885TDP1 4802/4885
US-20090081123-A1 PHARMACEUTICAL COMPOUNDS CNR2, CNR1, OPRK1 CNR2 1/4885CNR1 2/4885TDP1 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback